TETRAMODALITY TREATMENT OF HUMAN-MELANOMA IN-VITRO

被引：3

作者：

AUZENNE, E ^{[1
]}

FEIG, B ^{[1
]}

ROSS, MI ^{[1
]}

TOMASOVIC, SP ^{[1
]}

KLOSTERGAARD, J ^{[1
]}

机构：

[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030

来源：

MELANOMA RESEARCH | 1995年 / 5卷 / 01期

关键词：

CYTOTOXICITY; HUMAN; HYPERTHERMIA; IFN-GAMMA; L-PAM; MELANOMA; TNF;

D O I：

10.1097/00008390-199502000-00006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We evaluated the in vitro cytotoxic effects of combined human tumour necrosis factor alpha (TNF), human interferon gamma (IFN-gamma), melphalan (L-PAM) and hyperthermia (HTX) on human melanoma cell lines using the crystal violet assay. HTX (40-degrees-C, 1 h) alone had no effect. The responses of the cell lines to TNF were in the rank order of 939 cells > 987 > 284 > C8161 > 852 > A2058 approximately 0, and all displayed shallow dose-response curves; no significant thermal enhancement of TNF cytotoxicity was apparent with this heat dose. All cell lines were sensitive to L-PAM, with 284 cells being the most sensitive; HTX caused only slightly increased sensitization to L-PAM. The combination of TNF and L-PAM resulted in generally subadditive or additive cytotoxicity, with or without HTX. The response to IFN-gamma alone was heterogeneous; the 939, 284 and 852 cell lines were sensitive to a dose as low as 20 ng/ml, whereas the 987 line was resistant to 2.0 mug/ml, even with HTX. IFN-gamma enhanced the response to TNF only of the TNF-resistant A2058 cell line, but there was no enhancement of the response to L-PAM for any line. Thus, this tetramodality combination achieved generally subadditive or additive cytoxicity in vitro.

引用

页码：49 / 57

页数：9

共 25 条

[1]

Lienard D., Ewalenko P., Delmotte J.J., Et al., High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, J Clin Oncol, 10, pp. 52-60, (1992)

[2]

Lienard D., Lejeune F.J., Ewalenko P., In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-γ and melphalan in isolation perfusion, World Surg, 16, pp. 234-240, (1992)

[3]

Lienard D., Eggermont A.M.M., Schraffordt Koops H., Et al., Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and melphalan for melanoma stage III. Results of a multicentre pilot study, Melanoma Res, 4, pp. 21-26, (1994)

[4]

Schraffordt Koops H., Kroon B., Lejeune F.J., Isolated regional perfusion in the treatment of local recurrence, satellites and in-transit metastases of extremity melanomas, Therapy of Advanced Malignant Melanoma, Pigment Cell Series, pp. 67-78, (1990)

[5]

Kroon B.B.R., Klaase J.M., Van Geel A.N., Et al., Applications of hyperthermia in regional isolated perfusion of melanoma of the limbs, Reg Cancer Treat, 4, pp. 223-226, (1992)

[6]

Klostergaard J., Batta M., Tomasovi S.P., Hyperthermie modulation of tumor necrosis factor-dependent monocyte/macrophage tumor cytotoxicity in vitro, J Biol Resp Mod, 8, pp. 262-277, (1989)

[7]

Tomosovic S.P., Barta M., Klostergaard J., Temporal dependence of hyperthermic augmentation of macrophage-TNF production and tumor cell-TNF sensitization, Int J Hyperthermia, 5, pp. 625-639, (1989)

[8]

Watanabe N., Niitzu Y., Umeno H., Et al., Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia, Cancer Res, 48, pp. 650-653, (1988)

[9]

Fiers W., Brouckaert P., Guisetz Y., Recombinant interferon-γ and its synergism with tumor necrosis factor in the human and mouse systems, The Biology of the Interferon System, pp. 241-248, (1986)

[10]

Sohmura Y., Antitumor effect of recombinant human tumor necrosis factor alpha and its augmentation in vitro and in vivo, Tumor Necrosis Factor/Cachectin and Related Cytokines, pp. 189-195, (1988)

← 1 2 3 →